



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Registry of Cases of Pulmonary Hypertension in Army Hospitals

Thesis

*Submitted for Partial Fulfillment of MD in
Chest Diseases*

Presented by
Ahmed Mohamed Rafat Zaki
M.Sc Ain Shams University

Under the supervision of
Prof. Dr. Emad Elden Abd Elwahab Koraa
Professor of Chest Diseases
Faculty of Medicine - Ain Shams University

Prof. Dr. Ayman Abd Elhamid Farghaly
Professor of Chest Diseases
Military Medical Academy

Prof. Dr. Khaled Mohamed Wagih
Professor of Chest Diseases
Faculty of Medicine - Ain Shams University

Prof. Dr. Eman Ramzy Ali
Professor of Chest Diseases
Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2021

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Emad Elden Abd Elwahab Koraa**, Professor of Chest Diseases Faculty of Medicine - Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Ayman Abd Elhamid Farghaly**, Professor of Chest Diseases Military Medical Academy, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Prof. Dr. Khaled Mohamed Wagih**, Professor of Chest Diseases Faculty of Medicine - Ain Shams University, for his great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Prof. Dr. Eman Ramzy Ali**, Professor of Chest Diseases Faculty of Medicine - Ain Shams University, for her kindness, supervision and cooperation in this work.*

*Special thanks are due to **Dr. Marwa M. Abdelrady**, Consultant of Chest Diseases, Air Forces Specialized Hospital, for her sincere efforts, fruitful encouragement.*

Ahmed Rafat

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations.....	v
Introduction	1
Aim of the Work	4
Review of Literature	
Pulmonary Hypertension.....	5
Right Heart Catheterization.....	43
Registries.....	64
Subjects and Methods.....	75
Results	87
Discussion	93
Summary	103
Conclusion	106
Recommendations	107
References	108
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Comprehensive clinical classification of pulmonary hypertension. ⁽¹⁾	8
Table (2):	Haemodynamic definitions of pulmonary hypertension. ⁽¹⁾	9
Table (3):	Updated risk level of drugs and toxins known to induce pulmonary arterial hypertension. ⁽¹⁾	13
Table (4):	Echocardiographic probability of pulmonary hypertension in symptomatic patients with a suspicion of pulmonary hypertension. ⁽¹⁾	30
Table (5):	Echocardiographic signs suggesting pulmonary hypertension used to assess the probability of pulmonary hypertension in addition to tricuspid regurgitation velocity measurement	31
Table (6):	Risk assessment in pulmonary arterial hypertension. ⁽¹⁾	38
Table (7):	Recommendations for right heart catheterization in pulmonary hypertension.	46
Table (8):	Recommendations for vasoreactivity testing.....	59
Table (9):	Practical recommendations relating to parameters measured or derived from right heart catheterization.....	60
Table (10):	Baseline characteristics of the studied population:	87
Table (11):	Group 1 classification among studied patients: ..	89
Table (12):	Functional class classification among studied patients:	89
Table (13):	6MWT data among studied patients:	89

List of Tables Cont...

Table No.	Title	Page No.
Table (14):	Hemodynamics data among studied patients:	90
Table (15):	Echocardiography data among studied patients:.....	91
Table (16):	Treatment options among studied patients:.....	92

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Survival in PAH after diagnosis in patients with existing.....	11
Figure (2):	The pie chart on the left shows the causes of Pulmonary arterial hypertension.....	12
Figure (3):	Schematic diagram of a pulmonary vascular cell showing the possible mechanisms leading to vasoconstriction and/or proliferation of the pulmonary vascular component cells	16
Figure (4):	Diagnostic algorithm of PH. ⁽¹⁾	35
Figure (5):	Evidence based treatment algorithm for pulmonary arterial hypertension patients	42
Figure (6):	The double lumen balloon flotation catheter and its placement at the bedside without fluoroscopy and by monitoring intracardiac pressures.....	44
Figure (7):	Pulmonary Artery (Swan-Ganz) Catheter. ⁽⁸⁴⁾	48
Figure (8):	Best practice recommendations for right heart catheterization: pressure transducer and zeroing	52
Figure (9):	Representative pressure tracings of a) pulmonary arterial pressure and b) pulmonary arterial wedge pressure (PAWP). ⁽⁸⁷⁾	54
Figure (10):	Pulmonary artery catheter (7.5 F) used for collecting hemodynamic measurements	78

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (11):	Cardiac catheterization laboratory outfitted with computerized hemodynamic monitoring systems used by chest specialized hospital Kobry Elkobba Armed Forces.....	80
Figure (12):	Age.....	88
Figure (13):	Group classification.	88
Figure (14):	Acute vasoreactivity.	91
Figure (15):	Treatment strategies.....	92

List of Abbreviations

Abb.	Full term
5-HTT	5hydroxytryptamine transporter
6MWD	6-minute walking distance
6MWT	6-minute walking test
ABGs	Arterial blood gases
ADMA	Asymmetric dimethylarginine
BMP	Bone morphogenetic protein
BMPR	Bone morphogenetic protein receptor
BNP	Brain natriuretic peptide
BSA	Body surface area
cAMP	Cyclic adenosine monophosphate
CCB	Calcium channel blocker
cGMP	Cyclic guanosine monophosphate
CHD	Congenital heart diseases
CI	Cardiac index
CMPDs	Chronic myeloproliferative diseases
CMR	Cardiac magnetic resonance
CO	Cardiac output
COPD	Chronic obstructive pulmonary disease
CPET	Cardiopulmonary exercise testing
CRF	Chronic renal failure
CT	Computed tomography
CTD	Connective tissue disease
CTD	Connective tissue disease
CTEPH	Chronic thromboembolic pulmonary hypertension
CTEPH	Chronic thromboembolic pulmonary hypertension
DPAH	Drug-induced PAH

List of Abbreviations Cont...

Abb.	Full term
DPG	Diastolic pressure gradient
ECG	Electrocardiogram
EGF	Endothelial growth factor
EIF2AK4	Eukaryotic Translation initiation factor 2 alpha kinase 4
ERN	European Reference Networks
ERS.....	European Respiratory Society
ESC.....	European Society of Cardiology
ESC/ERS	European Society of Cardiology and the European Respiratory Society
ET-1	Endothelin-1
ETA.....	Endothelin A
ETB.....	Endothelin B
GD.....	Gaucher disease
GRACE	Good Research for Comparative Effectiveness
GSDs.....	Glycogen storage diseases
HFpEF.....	Heart failure with preserved ejection fraction
HIV	Human immunodeficiency virus
HPAH	Heritable pulmonary arterial hypertension
i.v.	Intravenous
IPAH.....	Idiopathic pulmonary arterial hypertension
KORPAH.....	Korean Registry of Pulmonary Arterial Hypertension
LV	Left ventricular
LVEDP	Left ventricular end-diastolic pressure
MAP	Mitogen-activated kinase
mPAP.....	Mean pulmonary arterial pressure
mSAP.....	Mean systemic arterial pressure
NHLBI.....	National Heart, Lung, and Blood Institute
NO	Nitric oxidase

List of Abbreviations Cont...

Abb.	Full term
NT-proBNP	N-terminal pro-brain natriuretic peptide
PA	Pulmonary artery
PAH	Pulmonary arterial hypertension
PAP	Pulmonary arterial pressure
PAPm.....	Mean pulmonary arterial pressure
PAWP	Pulmonary artery wedge pressure
PCA	Prostacyclin analogues
pCO ₂	Pressure of carbon dioxide
PDGF.....	Platelet-derived growth factor
PFT	Pulmonary function tests
PH.....	Pulmonary hypertension
PLCH.....	Pulmonary Langerhans cell histiocytosis
PPH	Primary PH
pred.....	Predicted
PVOD.....	Pulmonary veno-occlusive disease
PVOD/PCH.....	Pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis
PVR.....	Pulmonary vascular resistance
PVRI	Pulmonary vascular resistance index
RA.....	Right atrium
RAP.....	Right atrial pressure
REVEAL.....	Registry to Evaluate Early And Long-term PAH disease management
RHC	Right heart catheterization
RV	Right ventricular
RVP.....	Right ventricular pressure
SAPH.....	Sarcoid-associated pulmonary hypertension
SCD.....	Sickle cell disease
SNAP.....	Surveillance of North American Pulmonary Hypertension

List of Abbreviations Cont...

Abb.	Full term
SOPHIA.....	Surveillance of Pulmonary Hypertension in America
SSc	Systemic sclerosis
SvO ₂	Mixed venous oxygen saturation
SVR.....	Systemic vascular resistance
TGF- β	Transforming growth factor- β
TPG.....	Transpulmonary pressure gradient
V/Q.....	Ventilation/perfusion
VE/VCO ₂	Ventilator equivalents for carbon dioxide
VEGF	Vascular endothelial growth factor
VIP.....	Vasoactive intestinal peptide
VO ₂	Oxygen consumption
VPAC	VIP receptors
WHO	World Health Organization
WHO-FC.....	World Health Organization functional class
WSPH	World Symposium on PH
WU.....	Wood units

INTRODUCTION

Pulmonary hypertension (PH) is a progressive disorder characterized by abnormally elevated blood pressure of the pulmonary circulation which results, over time, from extensive vascular remodeling and increased pulmonary vascular resistance (PVR)⁽¹⁾.

Pulmonary arterial hypertension (PAH) is a subcategory of pulmonary hypertension (PH) that comprises a group of disorders with similar pulmonary vascular pathology. Though PH is common, the estimated incidence of IPAH is 1–3 cases per million, making it a rare disease ⁽¹⁾.

The hemodynamic definition of PAH is a mean pulmonary artery pressure at rest ≥ 25 mm Hg in the presence of a pulmonary capillary wedge pressure $15 \leq$ mmHg with pulmonary vascular resistance (PVR) greater than 3 WU. Specific maneuvers during right heart catheterization can be utilized to disclose vasoreactivity and heart failure with preserved ejection fraction, which have implications for management ⁽²⁾.

Right heart catheterization is the most powerful maneuver for diagnosis confirmation by measuring the mean pressure of the pulmonary artery. It can also give more information about cardiac output and estimation of the pressure of the left atrium in order to assess the pressures of the left side